Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines

Peter L. Greenberg; Richard M. Stone; Aref Al-Kali; John M. Bennett; Uma Borate; Andrew M. Brunner; Wanxing Chai-Ho; Peter Curtin; Carlos M. De Castro; H. Joachim Deeg; Amy E. DeZern; Shira Dinner; Charles Foucar; Karin Gaensler; Guillermo Garcia-Manero; Elizabeth A. Griffiths; David Head; Brian A. Jonas; Sioban Keel; Yazan Madanat; Lori J. Maness; James Mangan; Shannon McCurdy; Christine McMahon; Bhumika Patel; Vishnu V. Reddy; David A. Sallman; Rory Shallis; Paul J. Shami; Swapna Thota; Asya Nina Varshavsky-Yanovsky; Peter Westervelt; Elizabeth Hollinger; Dorothy A. Shead; Cindy Hochstetler

doi:10.6004/jnccn.2022.0009

Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, John M. Bennett, Uma Borate, Andrew M. Brunner, Wanxing Chai-Ho, Peter Curtin, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Shira Dinner, Charles Foucar, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Brian A. Jonas, Sioban Keel, Yazan MadanatLori J. Maness, James Mangan, Shannon McCurdy, Christine McMahon, Bhumika Patel, Vishnu V. Reddy, David A. Sallman, Rory Shallis, Paul J. Shami, Swapna Thota, Asya Nina Varshavsky-Yanovsky, Peter Westervelt, Elizabeth Hollinger, Dorothy A. Shead, Cindy Hochstetler

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.

Original language	English (US)
Pages (from-to)	106-117
Number of pages	12
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2022.0009
State	Published - Feb 2022

Funding

This activity is supported by educational grants from AstraZeneca; BeiGene; Exact Sciences; Gilead Sciences, Inc.; GlaxoSmithKline; Lantheus Medical Imaging Inc.; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Astellas. This activity is supported by an education grant from Astellas and Seagen Inc. This activity is supported by a medical education grant from Karyopharm® Therapeutics. This activity is supported through an Independent Medical Education grant from Merck & Co., Inc.

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2022.0009

Cite this

Greenberg, P. L., Stone, R. M., Al-Kali, A., Bennett, J. M., Borate, U., Brunner, A. M., Chai-Ho, W., Curtin, P., De Castro, C. M., Joachim Deeg, H., DeZern, A. E., Dinner, S., Foucar, C., Gaensler, K., Garcia-Manero, G., Griffiths, E. A., Head, D., Jonas, B. A., Keel, S., ... Hochstetler, C. (2022). Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 20(2), 106-117. https://doi.org/10.6004/jnccn.2022.0009

@article{6917c58a9c2c4bc295e40a0c86aeb584,

title = "Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.",

author = "Greenberg, {Peter L.} and Stone, {Richard M.} and Aref Al-Kali and Bennett, {John M.} and Uma Borate and Brunner, {Andrew M.} and Wanxing Chai-Ho and Peter Curtin and {De Castro}, {Carlos M.} and {Joachim Deeg}, H. and DeZern, {Amy E.} and Shira Dinner and Charles Foucar and Karin Gaensler and Guillermo Garcia-Manero and Griffiths, {Elizabeth A.} and David Head and Jonas, {Brian A.} and Sioban Keel and Yazan Madanat and Maness, {Lori J.} and James Mangan and Shannon McCurdy and Christine McMahon and Bhumika Patel and Reddy, {Vishnu V.} and Sallman, {David A.} and Rory Shallis and Shami, {Paul J.} and Swapna Thota and Varshavsky-Yanovsky, {Asya Nina} and Peter Westervelt and Elizabeth Hollinger and Shead, {Dorothy A.} and Cindy Hochstetler",

year = "2022",

month = feb,

doi = "10.6004/jnccn.2022.0009",

language = "English (US)",

volume = "20",

pages = "106--117",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2",

}

Greenberg, PL, Stone, RM, Al-Kali, A, Bennett, JM, Borate, U, Brunner, AM, Chai-Ho, W, Curtin, P, De Castro, CM, Joachim Deeg, H, DeZern, AE, Dinner, S, Foucar, C, Gaensler, K, Garcia-Manero, G, Griffiths, EA, Head, D, Jonas, BA, Keel, S, Madanat, Y, Maness, LJ, Mangan, J, McCurdy, S, McMahon, C, Patel, B, Reddy, VV, Sallman, DA, Shallis, R, Shami, PJ, Thota, S, Varshavsky-Yanovsky, AN, Westervelt, P, Hollinger, E, Shead, DA & Hochstetler, C 2022, 'Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 20, no. 2, pp. 106-117. https://doi.org/10.6004/jnccn.2022.0009

TY - JOUR

T1 - Myelodysplastic Syndromes, Version 3.2022

T2 - Featured Updates to the NCCN Guidelines

AU - Greenberg, Peter L.

AU - Stone, Richard M.

AU - Al-Kali, Aref

AU - Bennett, John M.

AU - Borate, Uma

AU - Brunner, Andrew M.

AU - Chai-Ho, Wanxing

AU - Curtin, Peter

AU - De Castro, Carlos M.

AU - Joachim Deeg, H.

AU - DeZern, Amy E.

AU - Dinner, Shira

AU - Foucar, Charles

AU - Gaensler, Karin

AU - Garcia-Manero, Guillermo

AU - Griffiths, Elizabeth A.

AU - Head, David

AU - Jonas, Brian A.

AU - Keel, Sioban

AU - Madanat, Yazan

AU - Maness, Lori J.

AU - Mangan, James

AU - McCurdy, Shannon

AU - McMahon, Christine

AU - Patel, Bhumika

AU - Reddy, Vishnu V.

AU - Sallman, David A.

AU - Shallis, Rory

AU - Shami, Paul J.

AU - Thota, Swapna

AU - Varshavsky-Yanovsky, Asya Nina

AU - Westervelt, Peter

AU - Hollinger, Elizabeth

AU - Shead, Dorothy A.

AU - Hochstetler, Cindy

PY - 2022/2

Y1 - 2022/2

N2 - The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.

AB - The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.

UR - http://www.scopus.com/inward/record.url?scp=85124256299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124256299&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2022.0009

DO - 10.6004/jnccn.2022.0009

M3 - Article

C2 - 35130502

AN - SCOPUS:85124256299

SN - 1540-1405

VL - 20

SP - 106

EP - 117

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this